Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injectable formulation for subcutaneous use. It functions as an immunosuppressant and antineoplastic agent, indicated for autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as for certain malignancies including acute lymphoblastic leukemia. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches for global distribution.

Methotrexate is employed in the management of inflammatory and malignant conditions where cell proliferation needs to be controlled.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: diminishes skin plaque formation and severity. Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. Osteosarcoma: used as part of combination chemotherapy to improve survival outcomes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes. - Transient decrease in blood cell counts.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Acute renal failure. - Anaphylactic or severe hypersensitivity reactions. - Myelosuppression leading to pancytopenia.

Careful monitoring and patient education are essential when using methotrexate.

Liver monitoring: perform baseline and periodic liver function tests. Blood count monitoring: check complete blood count regularly. Renal function: assess kidney function before and during therapy. Contraception: use effective birth control during treatment and for several months after discontinuation. Drug interactions: avoid concurrent use of nephrotoxic agents without medical supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate may interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - NSAIDs: increase risk of methotrexate toxicity and renal impairment. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Live vaccines: may cause severe infection in immunocompromised patients.

Moderate Interactions (Monitor Closely): - Azathioprine: combined immunosuppression may heighten infection risk. - Phenytoin: may reduce methotrexate plasma concentrations. - Folic acid supplementation: can lessen efficacy; dose adjustments should be guided by a clinician.